Xiao Ping Dai
Chief Tech/Sci/R&D Officer chez IVERIC BIO, INC.
Profil
Xiao Ping Dai is currently the Chief Technical Officer at IVERIC bio, Inc. Prior to this, she worked as the Senior Director-Biologics Development at Celgene Corp.
from 2014 to 2018, and as the Chief Technologist & VP-Technology Development at WuXi Advanced Therapies, Inc. from 2018 to 2019.
She holds a doctorate degree from the New Jersey Institute of Technology.
Postes actifs de Xiao Ping Dai
Sociétés | Poste | Début |
---|---|---|
IVERIC BIO, INC. | Chief Tech/Sci/R&D Officer | - |
Anciens postes connus de Xiao Ping Dai
Sociétés | Poste | Fin |
---|---|---|
WuXi Advanced Therapies, Inc.
WuXi Advanced Therapies, Inc. Pharmaceuticals: MajorHealth Technology Part of WuXi AppTec Co., Ltd., WuXi Advanced Therapies, Inc. is a contract testing development and manufacturing organization (CTDMO) based in Philadelphia, PA. The private company offers integrated platforms to transform the discovery, development, testing, manufacturing, and commercialization of cell and gene therapies for customers worldwide. The company's technologies, automation platforms, and service solutions advance pre-clinical research and accelerate the timeline to GMP manufacture, while integrated GMP manufacturing and testing platforms reduce time to market, maintaining high titers, high levels of quality assurance, and full regulatory compliance. Ultimately, their complete end-to-end solutions support pioneering companies to deliver breakthrough cell and gene therapies to the patients who need them. | Chief Tech/Sci/R&D Officer | 01/10/2019 |
CELGENE | Corporate Officer/Principal | 01/06/2018 |
Formation de Xiao Ping Dai
New Jersey Institute of Technology | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 3 |
---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
IVERIC bio, Inc.
IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
WuXi Advanced Therapies, Inc.
WuXi Advanced Therapies, Inc. Pharmaceuticals: MajorHealth Technology Part of WuXi AppTec Co., Ltd., WuXi Advanced Therapies, Inc. is a contract testing development and manufacturing organization (CTDMO) based in Philadelphia, PA. The private company offers integrated platforms to transform the discovery, development, testing, manufacturing, and commercialization of cell and gene therapies for customers worldwide. The company's technologies, automation platforms, and service solutions advance pre-clinical research and accelerate the timeline to GMP manufacture, while integrated GMP manufacturing and testing platforms reduce time to market, maintaining high titers, high levels of quality assurance, and full regulatory compliance. Ultimately, their complete end-to-end solutions support pioneering companies to deliver breakthrough cell and gene therapies to the patients who need them. | Health Technology |